Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies

BACKGROUND: Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Singleton, Kyle W, Porter, Alyx B, Hu, Leland S, Johnston, Sandra K, Bond, Kamila M, Rickertsen, Cassandra R, De Leon, Gustavo, Whitmire, Scott A, Clark-Swanson, Kamala R, Mrugala, Maciej M, Swanson, Kristin R
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447137/
https://ncbi.nlm.nih.gov/pubmed/32864609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa085
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars